Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
about
MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesionsDNA methylation biomarkers: cancer and beyondGenomic data integration in chronic lymphocytic leukemia.Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development.Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization (iFISH)IGFBP-2 - taking the lead in growth, metabolism and cancerA Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?Isochromosome 17q in Chronic Lymphocytic Leukemia.BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients.Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicineCytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview.Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.Twist as a new prognostic marker in hematological malignancies.Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway.Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL.Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line.Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis.MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia.Interphase Molecular Cytogenetic Detection Rates of Chronic Lymphocytic Leukemia-Specific Aberrations Are Higher in Cultivated Cells Than in Blood or Bone Marrow Smears.Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD).Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemiaFludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia
P2860
Q26769953-2AA2F6BC-51A0-4EDD-B547-FCC20CAE475BQ26996421-2B017FBF-8C9F-487C-8B6D-2F77F8D3481AQ31147488-695D9689-E73C-4661-87D4-B8452A99B4D1Q33598691-7F76EE11-2452-46FA-9AD7-6E9C04B7C1DEQ34586721-91087722-6B94-41CB-9BA5-13EB01CFEACDQ35690628-3A66297E-88DA-485D-8FEC-5AFF583E8975Q35859176-408AD315-BA62-47A3-9B19-3DB9452AED1FQ36326271-83EC604D-F54F-4C46-BD32-EC5DFCAFA217Q36366951-C7ED7F26-6214-46D3-BE00-CF5574F5EB2BQ36825397-4EB51297-93DF-434C-A2CB-CB95A08DF41BQ37567005-2FCA2EB9-1061-4764-9169-05F236519A96Q38124319-0F64C540-98D3-488A-A871-442353C2C19BQ38156717-A6FC5CC1-0C46-4611-81D1-E6081B41F5E4Q38552664-F64ECE85-2DBD-4B9F-BC1A-B7AC744A5DE2Q38921580-F74F2DEA-59AF-49E5-956C-8949E04934E2Q38975200-4011065F-782C-41D3-AB10-4767C15A6A77Q38990718-D336E03D-801C-46B6-83F1-7D096818B0EDQ40042893-F6EDAC0D-2AA8-49C0-B6D5-8F99E1E68A93Q41316598-3DB2B4A9-FD63-4A54-9F6F-9691D8BF12BFQ42181437-A2255017-09B8-4949-BBA6-2E209436496EQ42383604-E83B6701-2CE3-42B4-9CEA-E0B101255C77Q43935580-D46B76A3-7A9F-4D8D-90DE-A34A9C17A926Q48141361-F75D115F-B18E-4341-8A3F-9FE70E057F7EQ50889845-46C6B49B-F01F-4E10-81A7-1D81681EBC65Q53381625-C1827DD2-DCCF-425F-BAF6-38F4F2885002Q54322737-6C1CC7DD-FB18-4BE9-972D-6F4A1C047793Q58041425-4DF5F602-7C16-48D7-AEDF-87130807E629Q58764409-AD726E2B-FFA3-4CAA-87EC-D395C970D84A
P2860
Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
@en
type
label
Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
@en
prefLabel
Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
@en
P1433
P1476
Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease
@en
P2093
Marcos González Díaz
P356
10.1016/J.CANCERGEN.2013.01.003
P577
2013-03-24T00:00:00Z